Anika Therapeutics | ANIK - Net Income


Anika Therapeutics reported $292K in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Abbott USD 1.08B 699M Mar/2026
Agenus USD -10.63M 74.49M Dec/2025
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Integra LifeSciences USD -4.62M 2.91M Mar/2026
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Merit Medical Systems USD 41M 2.99M Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Smith & Nephew USD 293M 79M Dec/2025
Stryker USD 745M 104M Mar/2026
Surmodics USD -5.32M 6.22M Jun/2025
Veracyte USD 28.71M 12.44M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026
Zimmer Biomet Holdings USD 238.1M 98.8M Mar/2026